Mark Pepys | Academic Influence

Q: What Schools Are Affiliated With Mark Pepys

Mark Pepys is affiliated with the following schools: University of Freiburg, Imperial College London, University College London, Charing Cross and Westminster Medical School, University of Wollongong, Royal Postgraduate Medical School, University of Toronto

Why Is Mark Pepys Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Sir Mark Brian Pepys is a South African-born British academic of medicine. He was until 2011 Professor of Medicine at University College London and Head of Medicine at the Hampstead Campus and the Royal Free Hospital.

(See a Problem?)

Mark Pepys's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

C-reactive protein: a critical update. (2003) (3974)
C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. (2004) (2975)
The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. (1994) (2483)
C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. (1999) (2025)
C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis (2010) (1950)
Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses (2000) (1725)
Common core structure of amyloid fibrils by synchrotron X-ray diffraction. (1997) (1567)
Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. (1983) (1272)
Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis (1997) (984)
C-reactive protein, fibrinogen, and cardiovascular disease prediction. (2012) (952)
The physiological structure of human C-reactive protein and its complex with phosphocholine. (1999) (759)
C-REACTIVE PROTEIN FIFTY YEARS ON (1981) (709)
Association between C-reactive protein and features of the metabolic syndrome: a population-based study. (2000) (706)
Targeting C-reactive protein for the treatment of cardiovascular disease (2006) (651)
Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. (1993) (637)
Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. (2002) (607)
Human lysozyme gene mutations cause hereditary systemic amyloidosis (1993) (582)
Effect of alcohol consumption on systemic markers of inflammation (2001) (567)
Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data (2011) (556)
Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity (1999) (539)
C-Reactive Protein and Complement Are Important Mediators of Tissue Damage in Acute Myocardial Infarction (1999) (536)
Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis (1993) (531)
Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein (2001) (523)
Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis (2002) (521)
Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. (1990) (503)
Structure of pentameric human serum amyloid P component (1994) (471)
C-Reactive Protein, Insulin Resistance, Central Obesity, and Coronary Heart Disease Risk in Indian Asians From the United Kingdom Compared With European Whites (2001) (459)
Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy (2003) (420)
Particulate air pollution is associated with an acute phase response in men; results from the MONICA-Augsburg Study. (2001) (417)
Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. (1995) (407)
Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. (1997) (395)
Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. (1982) (391)
Hormone binding globulins undergo serpin conformational change in inflammation (1988) (390)
Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP‐met30) (1991) (389)
ROLE OF COMPLEMENT IN INDUCTION OF ANTIBODY PRODUCTION IN VIVO (1974) (367)
The protofilament substructure of amyloid fibrils. (2000) (333)
Antibodies to human serum amyloid P component eliminate visceral amyloid deposits (2010) (311)
Solid phase radioimmunoassays for human C-reactive protein. (1981) (302)
Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. (2015) (296)
Three dimensional structure of human C-reactive protein (1996) (291)
Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. (2000) (290)
Serum amyloid P-component is an acute-phase reactant in the mouse (1979) (281)
Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene (1997) (266)
Risk factors for coronary heart disease and acute-phase proteins. A population-based study. (1999) (263)
Binding of serum amyloid P-component (SAP) by amyloid fibrils. (1979) (262)
C-reactive protein and cardiovascular disease: new insights from an old molecule. (2003) (262)
Temporary depletion of complement component C3 or genetic deficiency of C1q significantly delays onset of scrapie (2001) (250)
Human plasma fibrinogen is synthesized in the liver. (2007) (240)
Insulin as an amyloid-fibril protein at sites of repeated insulin injections in a diabetic patient (1988) (234)
SERUM AMYLOID-A PROTEIN CONCENTRATION IN INFLAMMATORY DISEASES AND ITS RELATIONSHIP TO THE INCIDENCE OF REACTIVE SYSTEMIC AMYLOIDOSIS (1982) (217)
Pathogenesis, diagnosis and treatment of systemic amyloidosis. (2001) (215)
Amyloid P-component is a constituent of normal human glomerular basement membrane (1980) (213)
Interleukin 6 Influences Germinal Center Development and Antibody Production via a Contribution of C3 Complement Component (1998) (211)
Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. (1994) (211)
Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system. (1997) (206)
DIAGNOSTIC RADIONUCLIDE IMAGING OF AMYLOID: BIOLOGICAL TARGETING BY CIRCULATING HUMAN SERUM AMYLOID P COMPONENT (1988) (204)
The genetic basis of autosomal dominant familial Mediterranean fever. (2000) (203)
Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. (2005) (202)
Analogues in other mammals and in fish of human plasma proteins, C-reactive protein and amyloid P component (1978) (201)
Complement Dependence of Localisation of Aggregated IgG in Germinal Centres (1975) (198)
Obesity Is an Important Determinant of Baseline Serum C-Reactive Protein Concentration in Monozygotic Twins, Independent of Genetic Influences (2004) (197)
Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis. (1998) (196)
Activation of mouse complement by different classes of mouse antibody. (1979) (194)
Amyloid P component is located on elastic fibre microfibrils in normal human tissue (1981) (193)
Plasma protein acute-phase response in unstable angina is not induced by ischemic injury. (1996) (193)
Serum amyloid P component is the major calcium-dependent specific DNA binding protein of the serum. (1987) (188)
Comparative clinical study of protein SAP (amyloid P component) and C-reactive protein in serum. (1978) (187)
Amyloid P component. A critical review (1997) (183)
Inflammation and Endothelial Function: Direct Vascular Effects of Human C-Reactive Protein on Nitric Oxide Bioavailability (2005) (181)
Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein (1982) (180)
Role of complement in induction of the allergic response. (1972) (176)
Enhanced inflammatory response in patients with preinfarction unstable angina. (1999) (175)
Genetic effects on baseline values of C-reactive protein and serum amyloid a protein: a comparison of monozygotic and dizygotic twins. (2004) (169)
AMYLOIDOSIS: A REVIEW OF RECENT DIAGNOSTIC AND THERAPEUTIC DEVELOPMENTS (1997) (169)
Correlation of clinical parameters of disease activity in rheumatoid arthritis with serum concentration of C-reactive protein and erythrocyte sedimentation rate. (1982) (164)
Value of serum C-reactive protein measurement in the investigation of fever in systemic lupus erythematosus. (1980) (163)
Hereditary systemic amyloidosis due to Asp76Asn variant β2-microglobulin. (2012) (162)
ISOLATION OF AMYLOID P COMPONENT (PROTEIN AP) FROM NORMAL SERUM AS A CALCIUM-DEPENDENT BINDING PROTEIN (1977) (158)
C-reactive protein: binding to lipids and lipoproteins. (1985) (156)
Acute phase response and evolution of familial Mediter ranean fever (1999) (154)
Role of serum amyloid P component in bacterial infection: protection of the host or protection of the pathogen. (2000) (153)
Isolation and characterization of C-reactive protein and serum amyloid P component in the rat. (1982) (151)
Proinflammatory Effects of Bacterial Recombinant Human C-Reactive Protein Are Caused by Contamination With Bacterial Products, Not by C-Reactive Protein Itself (2005) (148)
Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. (1998) (147)
Quantitative fecal indium 111-labeled leukocyte excretion in the assessment of disease in Crohn's disease. (1983) (147)
BIOLOGY OF SERUM AMYLOID P COMPONENT * (1982) (143)
Refinement of the association of serum C-reactive protein concentration and coronary heart disease risk by correction for within-subject variation over time: the MONICA Augsburg studies, 1984 and 1987. (2003) (140)
Rapid automated high sensitivity enzyme immunoassay of C-reactive protein. (1998) (138)
Differing acute phase responses in Crohn's disease and ulcerative colitis. (1986) (138)
C-reactive protein and atherothrombosis. (2001) (137)
Human C-Reactive Protein Increases Cerebral Infarct Size after Middle Cerebral Artery Occlusion in Adult Rats (2004) (135)
Serum amyloid A protein (SAA) in horses: objective measurement of the acute phase response. (1989) (130)
Acute phase response and evolution of familial Mediterranean fever. (1999) (128)
Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis (2010) (125)
Binding specificity of serum amyloid P component for the pyruvate acetal of galactose (1984) (123)
Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. (2006) (118)
Isolation of human C-reactive protein and serum amyloid P component. (1982) (114)
Pentameric and decameric structures in solution of serum amyloid P component by X-ray and neutron scattering and molecular modelling analyses. (1997) (113)
Pentraxin-chromatin interactions: serum amyloid P component specifically displaces H1-type histones and solubilizes native long chromatin (1990) (113)
CRP or not CRP? That is the question. (2005) (111)
Binding of pentraxins to different nuclear structures: C‐reactive protein binds to small nuclear ribonucleoprotein particles, serum amyloid P component binds to chromatin and nucleoli (1994) (111)
C-reactive protein in dogs. (1987) (110)
Role of Complement in the Induction of Immunological Responses (1976) (110)
Multinucleated Giant Cells Are Specialized for Complement-Mediated Phagocytosis and Large Target Destruction (2015) (109)
Structural diversity of ex vivo amyloid fibrils studied by cryo-electron microscopy. (2001) (108)
Infection with Helicobacter pylori is not a major independent risk factor for stable coronary heart disease: lack of a role of cytotoxin-associated protein A-positive strains and absence of a systemic inflammatory response. (1999) (108)
Transthyretin Leu12Pro is associated with systemic, neuropathic and leptomeningeal amyloidosis. (1999) (106)
Pyrin/marenostrin mutations in familial Mediterranean fever. (1998) (104)
Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis. (1990) (102)
The liver in systemic amyloidosis: insights from 123I serum amyloid P component scintigraphy in 484 patients (1998) (102)
A novel mechano-enzymatic cleavage mechanism underlies transthyretin amyloidogenesis (2015) (102)
SAA1 alleles as risk factors in reactive systemic AA amyloidosis. (1998) (101)
Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE-/- mice. (2008) (100)
Complement Factor H Binds to Denatured Rather than to Native Pentameric C-reactive Protein* (2008) (100)
Scintigraphic quantification and serial monitoring of human visceral amyloid deposits provide evidence for turnover and regression. (1993) (98)
Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein AI gene. (1996) (98)
The renaissance of C reactive protein (2001) (96)
C-reactive protein in SLE. (1982) (96)
Serum amyloid P component scintigraphy and turnover studies for diagnosis and quantitative monitoring of AA amyloidosis in juvenile rheumatoid arthritis. (1993) (91)
Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis (2018) (91)
Human serum amyloid P component, a circulating lectin with specificity for the cyclic 4,6-pyruvate acetal of galactose. Interactions with various bacteria. (1985) (88)
Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis (2014) (88)
The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo. (1994) (87)
Isolation of serum amyloid P-component (protein SAP) in the mouse. (1979) (87)
Circulating serum amyloid P component is the precursor of amyloid P component in tissue amyloid deposits. (1986) (86)
Specific localization and imaging of amyloid deposits in vivo using 123I-labeled serum amyloid P component (1988) (86)
Serum amyloid P component in chronic renal failure and dialysis. (1991) (85)
Comparative analyses of pentraxins: implications for protomer assembly and ligand binding. (1995) (84)
Serum amyloid P component scintigraphy in familial amyloid polyneuropathy: regression of visceral amyloid following liver transplantation (1998) (84)
C-reactive protein and cardiovascular disease: Weighing the evidence (2006) (84)
Pathogenetic mechanisms of amyloid A amyloidosis (2013) (81)
Amyloidosis: some recent developments. (1988) (81)
C-Reactive Protein, a Sensitive Marker of Inflammation, Predicts Future Risk of Coronary Heart Disease in Initially Healthy Middle-Aged Men (1998) (80)
Circulating human leucocyte elastase in patients with inflammatory bowel disease. (1985) (79)
Studies in vivo and in vitro of serum amyloid P component in normals and in a patient with AA amyloidosis (1991) (78)
Structure, Folding Dynamics, and Amyloidogenesis of D76N β2-Microglobulin (2013) (77)
Serum amyloid P component binds to cell nuclei in vitro and to in vivo deposits of extracellular chromatin in systemic lupus erythematosus (1989) (77)
Isolation and characterization of C-reactive protein from the dog. (1984) (77)
Immunohistochemical demonstration of amyloid P component in skin of normal subjects and patients with cutaneous amyloidosis (1981) (77)
Treatment of amyloidosis. (1995) (76)
Secondary structure prediction of human SAA1. Presumptive identification of calcium and lipid binding sites. (1986) (76)
Curative hepatorenal transplantation in systemic amyloidosis caused by the Glu526Val fibrinogen alpha-chain variant in an English family. (2000) (74)
Role of C3 in in vitro lymphocyte cooperation (1974) (74)
Human Serum Amyloid P Component is a Single Uncomplexed Pentamer in Whole Serum (2000) (74)
Hereditary renal amyloidosis associated with variant lysozyme in a large English family. (1999) (73)
Unicentric Castleman's disease complicated by systemic AA amyloidosis: a curable disease. (2002) (71)
Autoimmunity and glomerulonephritis in mice with targeted deletion of the serum amyloid P component gene: SAP deficiency or strain combination? (2004) (70)
Circulating human C-reactive protein binds very low density lipoproteins. (1984) (70)
Rapid automated enzyme immunoassay of serum amyloid A. (1994) (70)
Organ Transplantation in Hereditary Apolipoprotein AI Amyloidosis (2006) (70)
Imaging of haemodialysis-associated amyloidosis with 123I-serum amyloid P component (1991) (70)
Imaging amyloidosis with radiolabelled SAP (1995) (69)
Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component (2009) (68)
Infusion of Pharmaceutical-Grade Natural Human C-Reactive Protein Is Not Proinflammatory in Healthy Adult Human Volunteers (2014) (68)
Hereditary nephropathic systemic amyloidosis caused by a novel variant apolipoprotein A-I. (1998) (67)
Long term effect of renal transplantation on dialysis-related amyloid deposits and symptomatology. (1996) (67)
C-reactive protein levels in systemic lupus erythematosus: a classification criterion? (1980) (66)
HUMAN C-REACTIVE PROTEIN (1997) (66)
Isolation and characterization of the integral glycosaminoglycan constituents of human amyloid A and monoclonal light-chain amyloid fibrils. (1991) (66)
The acute phase response and C-reactive protein (2010) (66)
Isolation of C-reactive protein by affinity chromatography. (1977) (65)
Trapping of palindromic ligands within native transthyretin prevents amyloid formation (2010) (64)
C-reactive protein and serum amyloid P component in the plaice (Pleuronectes platessa L.), a marine teleost, are homologous with their human counterparts. (1982) (63)
Long-term survival in systemic amyloid A amyloidosis complicating Crohn's disease. (1997) (62)
Domino hepatic transplantation using the liver from a patient with familial amyloid polyneuropathy. (1998) (61)
C-reactive protein and coronary disease: is there a causal link? (2009) (59)
Primary localised amyloidosis of the orbit. (1996) (58)
Human serum amyloid P component protects against Escherichia coli O157:H7 Shiga toxin 2 in vivo: therapeutic implications for hemolytic-uremic syndrome. (2006) (57)
Induction in mice of human light-chain-associated amyloidosis. (1992) (57)
A novel variant of transthyretin, 59Thr-->Lys, associated with autosomal dominant cardiac amyloidosis in an Italian family. (1995) (56)
Production of Granulocyte Colony-Stimulating Factor in the Nonspecific Acute Phase Response Enhances Host Resistance to Bacterial Infection1 (2002) (56)
Correlation in rheumatoid arthritis of concentrations of plasma C3d, serum rheumatoid factor, immune complexes and C-reactive protein with each other and with clinical features of disease activity. (1982) (55)
Molecular chaperone properties of serum amyloid P component (2000) (55)
IMMUNOHISTOCHEMICAL DEMONSTRATION OF AMYLOID P COMPONENT IN CEREBRO‐VASCULAR AMYLOIDOSIS (1984) (53)
Immunological studies in inflammatory bowel disease. (1977) (52)
C‐reactive protein in patients undergoing cardiac surgery (1986) (52)
Studies in vivo of cobra factor and murine C3. (1975) (52)
AMYLOID P-COMPONENT IN HUMAN GLOMERULAR BASEMENT MEMBRANE Abnormal Patterns of Immunofluorescent Staining in Glomerular Disease (1980) (52)
Calcium-dependent aggregation of human serum amyloid P component. (1982) (52)
Plasminogen activation triggers transthyretin amyloidogenesis in vitro (2018) (52)
Serum amyloid A protein is a clinically useful indicator of acute renal allograft rejection. (1997) (52)
Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis (1998) (51)
The first international standard for serum amyloid A protein (SAA). Evaluation in an international collaborative study. (1998) (50)
SPECIFIC CHEMICAL DISSOCIATION OF FIBRILLAR AND NON-FIBRILLAR COMPONENTS OF AMYLOID DEPOSITS (1984) (50)
Transthyretin gene analysis in European patients with suspected familial amyloid polyneuropathy. (1995) (50)
Transthyretin gene analysis in European patients with suspected familial amyloid polyneuropathy (1996) (50)
Monitoring the acute phase response to vaso-occlusive crisis in sickle cell disease. (1994) (49)
Immunohistochemical studies of amyloid P component distribution in normal human skin. (1983) (48)
Concentration of serum amyloid P component in the CSF as a possible marker of cerebral amyloid deposits in Alzheimer's disease. (1994) (48)
Preprocedural inflammatory markers do not predict restenosis after successful coronary stenting. (2004) (47)
Lack of seasonal variation in C-reactive protein. (2002) (47)
Differences in the acute phase responses of serum amyloid P-component (SAP) and C3 to injections of casein or bovine serum albumin in amyloid-susceptible and -resistant mouse strains. (1980) (45)
Crystal structure of a decameric complex of human serum amyloid P component with bound dAMP. (1997) (45)
Glycobiology of the pentraxins. (1994) (45)
Rheumatoid arthritis: the role of acute-phase proteins. (1993) (44)
The membrane phenotype of T-prolymphocytic leukaemia. (2009) (43)
Quantitation of human leukocyte elastase, cathepsin G, alpha-2-macroglobulin and alpha-1-proteinase inhibitor in osteoarthrosis and rheumatoid arthritis synovial fluids. (1984) (43)
Rabbit and rat C-reactive proteins bind apolipoprotein B-containing lipoproteins (1984) (41)
Anti-keratin antibodies in rheumatoid arthritis: frequency and correlation with other features of the disease. (1983) (41)
Amyloid and the gut. (1997) (40)
C-reactive protein is essential for innate resistance to pneumococcal infection (2014) (40)
Identification and isolation of two pentraxins from bovine serum. (1987) (40)
Serum C-reactive protein in polymyalgia rheumatica. A prospective serial study. (1985) (40)
Serum C-reactive protein measurement in the detection of intercurrent infection in Oriental patients with systemic lupus erythematosus. (1985) (39)
Serum C-reactive protein levels in the management of infection in acute leukaemia. (1984) (39)
C-reactive protein is neither a marker nor a mediator of atherosclerosis (2008) (38)
Inhibition by C3 fragments of C3-dependent rosette formation and antigen-induced lymphocyte transformation. (1974) (38)
Cambridge University Natural Science Club, 1872 to 1972 (1972) (38)
HAEMODIALYSIS VERSUS CAPD: EQUAL PREDISPOSITION TO AMYLOIDOSIS? (1986) (38)
Distribution and determinants of circulating complement factor H concentration determined by a high-throughput immunonephelometric assay. (2013) (37)
Amyloid P component binds to keratin bodies in human skin and to isolated keratin filament aggregates in vitro. (1988) (37)
Molecular characterization of Limulus polyphemus C-reactive protein. I. Subunit composition. (1993) (37)
Human C-Reactive Protein Does Not Protect against Acute Lipopolysaccharide Challenge in Mice 1 (2003) (37)
High-dose melphalan and stem cell rescue for AL amyloidosis (1999) (37)
A primed state exists in vivo following histological regression of amyloidosis (1990) (36)
Mechanisms of Schistosoma mansoni egg excretion: Parasitological observations in immunosuppressed mice reconstituted with immune serum (1983) (36)
Determination of C-reactive protein: comparison of three high-sensitivity immunoassays. (2003) (36)
The Pentraxins 1975–2018: Serendipity, Diagnostics and Drugs (2018) (36)
Isolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and C‐reactive protein, for clinical use (2012) (35)
Complement independence of stimulation of mouse splenic B lymphocytes by mitogens. (1973) (35)
Amyloid P-component in mice injected with casein: identification in amyloid deposits and in the cytoplasm of hepatocytes. (1980) (34)
In vivo turnover studies of C-reactive protein. (1985) (33)
Tissue amyloid P component in normal human dermis is non-covalently associated with elastic fiber microfibrils. (1989) (33)
Structural basis of ligand specificity in the human pentraxins, C‐reactive protein and serum amyloid P component (2011) (33)
C-reactive protein in healthy and in sick populations. (2000) (33)
A pentameric form of human serum amyloid P component. Crystallization, X-ray diffraction and neutron scattering studies. (1988) (33)
The structures of crystalline complexes of human serum amyloid P component with its carbohydrate ligand, the cyclic pyruvate acetal of galactose. (2002) (33)
MHC typing in variant Creutzfeldt-Jakob disease (2003) (32)
Markers of inflammation in women on different hormone replacement therapies (2003) (32)
Familial amyloidosis of Ostertag. (1982) (31)
Agglutination of complement-coated erythrocytes by serum amyloid P-component. (1981) (31)
Isolation and Characterization of Amyloid Enhancing Factor (AEF) (1986) (31)
Congo red overlay immunohistochemistry aids classification of amyloid deposits (1999) (30)
Hereditary cardiac amyloidosis associated with the transthyretin Ile122 mutation in a white man (1999) (30)
Inhibition of the mechano-enzymatic amyloidogenesis of transthyretin: role of ligand affinity, binding cooperativity and occupancy of the inner channel (2017) (30)
C-Reactive Protein Risk Prediction: Low Specificity, High Sensitivity (2002) (29)
Isolation and study of murine C3. (1977) (29)
Clinical, radiological and serum amyloid P component scintigraphic features of beta2-microglobulin amyloidosis associated with continuous ambulatory peritoneal dialysis. (1999) (28)
Plasma leucocyte elastase concentrations in smokers. (1991) (28)
Science and serendipity. (2007) (28)
Measurement of serum amyloid A protein (SAA) as an aid to differential diagnosis of infection in newborn foals (1992) (27)
Comparison of the role of complement in immunity to Schistosoma mansoni in rats and mice. (1988) (27)
DIURNAL VARIATION OF ERYTHROCYTE SEDIMENTATION RATE RELATED TO FEEDING (1982) (27)
Primary Localized Orbital Amyloidosis Composed of the Immunoglobulin γ Heavy Chain CH3 Domain (1994) (26)
Tissue vitronectin in normal adult human dermis is non-covalently bound to elastic tissue. (1991) (26)
Serum protein concentrations during Schistosoma mansoni infection in intact and T-cell deprived mice. I. The acute phase proteins, C3 and serum amyloid P-component (SAP). (1980) (26)
An improved method for the isolation from Naja naja venom of cobra factor (CoF) free of phospholipase A. (1979) (25)
Immunochemical cross-reactions between pentraxins of different species. (1987) (25)
Calcium-dependent aggregation of human serum amyloid P component. Inhibition by the cyclic 4,6-pyruvate acetal of galactose. (1984) (25)
Acute Phase Proteins in the Acute Phase Response (2012) (24)
Studies of the in vivo synthesis and catabolism of serum amyloid P component (SAP) in the mouse. (1985) (24)
Immunohistochemical studies of amyloid P component in disorders of cutaneous elastic tissue (1982) (24)
Scintigraphy with 123I-serum amyloid P component in Alzheimer disease. (1998) (24)
C-reactive protein: the role of an ancient protein in modern rheumatology. (1983) (22)
Experimental amyloidosis in the hamster: correlation between hamster female protein levels and amyloid deposition. (1989) (22)
Enumeration of lymphocyte populations in whole peripheral blood with alkaline phosphatase-labelled reagents. A method for routine clinical use. (1977) (22)
HUMAN C-REACTIVE PROTEIN COMPLEXED WITH PHOSPHOCHOLINE (1999) (22)
Demonstration of amyloid A (AA) protein and amyloid P component (AP) in deposits of systemic amyloidosis associated with renal adenocarcinoma (1983) (22)
Enumeration of immunoglobulin-bearing lymphocytes in whole peripheral blood. (1976) (22)
Immunosuppression by cobra factor: distribution, antigen-induced blast transformation and trapping of lymphocytes during in vivo complement depletion. (1976) (22)
Pharmacological removal of serum amyloid P component from intracerebral plaques and cerebrovascular Aβ amyloid deposits in vivo (2016) (21)
Solid-phase immunoradiometric assay for serum amyloid A protein using magnetisable cellulose particles. (1982) (21)
Molecular characterization of Limulus polyphemus C-reactive protein. II. Asparagine-linked oligosaccharides. (1993) (21)
Measurement of serum C reactive protein concentration after bone marrow transplantation for leukaemia. (1984) (21)
Isolation and characterization of goat C-reactive protein (1987) (21)
Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes (2019) (21)
Lack of Effect of a Single Injection of Human C-Reactive Protein on Murine Lupus or Nephrotoxic Nephritis (2009) (21)
Solid-phase immunoradiometric assay for C-reactive protein using magnetisable cellulose particles. (1982) (20)
Molecular mechanisms of fibrillogenesis and the protective role of amyloid P component: two possible avenues for therapy. (1996) (20)
Amyloid P component and the diagnosis of amyloidosis (1992) (20)
Acute-phase high-density lipoprotein in the rat does not contain serum amyloid A protein. (1987) (20)
Imaging of experimental amyloidosis with 131I-labeled serum amyloid P component. (1987) (20)
C-reactive protein as an index of disease activity. Comparison of tenidap, cyclophosphamide and dexamethasone in rat adjuvant arthritis. (1991) (19)
X-ray scattering and diffraction by wet gels of AA amyloid fibrils. (1986) (19)
C-reactive protein predicts outcome in COVID-19: is it also a therapeutic target? (2021) (19)
Protection of Human Podocytes from Shiga Toxin 2-Induced Phosphorylation of Mitogen-Activated Protein Kinases and Apoptosis by Human Serum Amyloid P Component (2014) (19)
Ultrastructural localization of amyloid P component in primary localized cutaneous amyloidosis (1983) (18)
Tolerance and immunity to the inducible self antigen C‐reactive protein in transgenic mice (1995) (18)
Amyloid P-Component: Structure and Properties (1986) (18)
C-reactive protein in childhood dermatomyositis (1982) (18)
C-reactive protein and the acute phase response (1982) (18)
Radiometric ligand binding assay for C-reactive protein. Complexed C-reactive protein is not detectable in acute phase serum. (1982) (17)
The acute phase response in parasite infection. Nippostrongylus brasiliensis in the mouse. (1984) (17)
Influenza Virus Infection is not Affected by Serum Amyloid P Component (2002) (16)
Plasma levels of inhibitor-bound leukocytic elastase in rheumatoid arthritis patients. (1984) (16)
Renal transplantation for amyloid end-stage renal failure-insights from serial serum amyloid P component scintigraphy (2000) (16)
Myelosclerosis and paroxysmal nocturnal haemoglobinuria. (2009) (16)
Serum C-reactive protein in primary Sjögren's syndrome. (1983) (16)
Campylobacter pylori, duodenal ulcer disease, and gastrin. (1989) (16)
A novel variant of human lysozyme (T70N) is common in the normal population. (2000) (15)
Effects of human chorionic gonadotropin preparations on complement in vitro. (1975) (15)
C-reactive protein and its role in the pathogenesis of myocardial infarction. (2001) (15)
Complement-mediated mixed aggregation of murine spleen cells (1974) (15)
Correlation of disease activity in systemic vasculitis with serum C‐reactive protein measurement. A prospective study of thirty‐eight patients (1985) (15)
Complement in the induction of IgE antibody formation. (1977) (15)
Serum amyloid P-component and C-reactive protein in serum of healthy Icelanders and members of an Icelandic family with macroglobulinaemia. (2009) (15)
Production of Granulocyte Colony Stimulating Factor Enhances Host Resistance to Bacterial Infection in the Acute Phase Response (2001) (14)
Serum C-Reactive Protein, Serum Amyloid P-Component and Serum Amyloid A Protein in Autoimmune Disease (1981) (14)
Amino acid sequence homology between rat and human C-reactive protein. (1984) (14)
A novel variant of human lysozyme (T70N) is common in the normal population (2000) (14)
Increasing the accuracy of proteomic typing by decellularisation of amyloid tissue biopsies (2017) (13)
Cell-mediated immunological responsiveness in mice decomplemented with cobra venom factor. (1978) (13)
Invasive candidiasis: new insights presaging new therapeutic approaches? (2012) (13)
Primary localized cutaneous amyloidosis: dermal amyloid deposits do not bind antibodies to amyloid A protein, prealbumin or fibronectin (1982) (13)
CLINICAL MEASUREMENT OF SERUM C‐REACTIVE PROTEIN IN THE MONITORING AND DIFFERENTIAL DIAGNOSIS OF INFLAMMATORY DISEASES AND TISSUE NECROSIS AND IN THE RECOGNITION AND MANAGEMENT OF INTERCURRENT INFECTION (1982) (13)
Amyloidosis (1994) (13)
Murine type II collagen arthritis. Association of an acute-phase response with clinical course. (1986) (13)
Hereditary amyloidosis [2] (multiple letters) (2002) (13)
Immunohistochemical studies of amyloid P component and fibronectin in erythropoietic protoporphyria (1983) (13)
Randomized phase I trial HIV-CORE 003: Depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV-1 (2018) (13)
Normal circulating serum amyloid P component concentration in systemic sclerosis. (2007) (13)
Studies of human serum amyloid P-component (SAP) in relation to coagulation. (1980) (13)
Inhibition of complement-dependent rosette formation after lymphocyte incubation with fatty acids. (1979) (12)
Is the serum amyloid A protein in acute phase plasma high density lipoprotein the precursor of AA amyloid fibrils? (1986) (12)
Apolipoprotein E4 genotype is not a risk factor for systemic AA amyloidosis or familial amyloid polyneuropathy (1995) (12)
β-Edge Interactions in a Pentadecameric Human Antibody Vκ Domain (2007) (12)
A molecular correlate of clinicopathology in transthyretin amyloidosis (2009) (12)
Characteristic and Clinical Outcome of 340 Patients with Systemic AA Amyloidosis (2004) (12)
Measurement of serum amyloid A protein concentrations as test of renal allograft rejection. (1984) (12)
C-reactive protein and apoB containing lipoproteins are associated with Mycobacterium leprae in lesions of human leprosy. (1984) (11)
Acetazolamide and renal stone formation. (1970) (11)
Amyloid and amyloidosis (1998) (11)
Serum amyloid P component (not Serum Amyloid Protein) (1999) (11)
Left atrial myxoma associated with systemic AA amyloidosis. (1989) (11)
Studies of the structure and binding properties of hamster female protein. (1993) (11)
AL kappa amyloid in a solitary extradural lymphoma. (1994) (11)
Immunodeficiency, malabsorption and secretory diarrhea. A new syndrome. (1979) (10)
Delayed hypersensitivity reactions to Listeria monocytogenes in rats decomplemented with cobra factor and in C5-deficient mice. (1981) (10)
Interaction of serum amyloid P component with hexanoyl bis(d-proline) (CPHPC) (2014) (10)
THE INTERACTION BETWEEN HUMAN SERUM AMYLOID P COMPONENT [SAP] AND FIXED COMPLEMENT (1982) (10)
The MHC class II-restricted T cell response of C57BL/6 mice to human C-reactive protein: homology to self and the selection of T cell epitopes and T cell receptors. (1997) (10)
Measurement of serum C-reactive protein concentration after renal transplantation. (1987) (9)
Echocardiographic assessment of cardiac involvement in systemic AL amyloidosis in relation to whole body amyloid load measured by serum amyloid P component (SAP) clearance. (1997) (9)
Complement‐independence of tolerance induction (1974) (9)
Primary localized orbital amyloidosis composed of the immunoglobulin gamma heavy chain CH3 domain. (1994) (9)
Human plasma ﬁbrinogen is synthesized in the liver (2007) (9)
Pathogenetic Mechanisms and Precursor Product Relationships in Murine Amyloidosis (1986) (9)
Enumeration of T and B lymphocytes in whole peripheral blood: absence of a null cell population. (1981) (9)
Enumeration in whole peripheral blood of lymphocytes bearing receptors for Fc(gamma) and C3b using alkaline phosphatase-labelled reagents. (1980) (9)
3 New amyloidogenic TTR mutations: Pro12, Glu18, and Val33 (1996) (9)
Isolation and characterization of guinea-pig serum amyloid P component. (1986) (8)
Enumeration of lymphocyte populations defined by surface markers in the whole blood of patients with Crohn's disease. (1982) (8)
Radioimmunoassay for immunoconglutinins. (1980) (8)
Correlation Between Sequence Variability and Structure Prediction in AA Proteins (1986) (8)
The liver in systemic amyloidosis: Insights from I-123-serum amyloid P component scintigraphy (1997) (8)
Is leptin an important physiological regulator of CRP? (2007) (8)
UK experience of liver transplantation in FAP (1996) (8)
Plasmin activity promotes amyloid deposition in a transgenic model of human transthyretin amyloidosis (2021) (7)
C-Reactive Protein (1998) (7)
In vivo turnover studies of C-reactive protein and lipoproteins in the rabbit. (1984) (7)
The failure of ascorbic acid therapy to alter the induction or remission of murine amyloidosis. (1984) (7)
Amyloid P component. (1997) (7)
Targeted treatment for amyloidosis. (2014) (7)
Curative hepatorenal transplantation for systemic amyloidosis associated with fibrinogen alpha-chain Glu526Val in an English family (1999) (7)
THE ACUTE PHASE REACTION IN EXPERIMENTAL INFECTIONS. ROLE OF THE SPECIFIC HOST IMMUNOLOGICAL RESPONSE AND DIFFERENT PATTERNS IN DIFFERENT ACUTE PHASE REACTANTS (1982) (7)
Immunoradiometric assay for human serum amyloid P component. (2011) (7)
Monitoring systemic amyloidosis using MRI measurements of the extracellular volume fraction (2013) (7)
Occult adrenal insufficiency secondary to amyloidosis in the context of chronic renal failure. (1995) (7)
17. SAP scintigraphy and turnover studies demonstrate regression of amyloidosis (1993) (7)
Amyloid (type AA) in a patient with hypogammaglobulinemia. (1985) (6)
Suppression of iga antibody production by in vivo complement depletion. (1976) (6)
Enumeration of lymphocyte populations in whole peripheral blood of patients with antibody-mediated nephritis during treatment with cyclosporin A. (1982) (6)
Non-Invasive Techniques for Demonstrating Cardiac Involvement in the Acquired Forms of Systemic Amyloidosis (1986) (6)
AA amyloid deposition is complement independent (2001) (6)
Comparative study of the stabilities of synthetic in vitro and natural ex vivo transthyretin amyloid fibrils (2020) (6)
Lymphocyte binding of fluid phase mouse C3b. (1979) (6)
Hereditary Renal Amyloidosis in a German Family Associated with Fibrinogen A _ Chain Glu540Val (2004) (5)
'Amyloid degrading activity' of human serum, an in vitro clearing effect which does not involve degradation of amyloid fibrils. (1984) (5)
C-reactive protein and the acute phase response. (1982) (5)
Outcome in systemic AL amyloidosis following stem cell transplantation or infusional chemotherapy. (2002) (5)
Immunoassays for Acute Phase Proteins (1981) (5)
Objective Monitoring of Disease Activity in Wegener's Granulomatosis by Measurement of Serum C-Reactive Protein Concentration (1984) (5)
Equilibrium contrast CMR for the detection of amyloidosis in mice (2011) (5)
Cumulative SAA production and outcome of AA amyloidosis (1999) (5)
AL amyloidosis Sequential heart and autologous stem cell transplantation for systemic (2013) (5)
Complement-independence of the acute-phase production of serum amyloijd P-component (SAP) in mice. (1980) (5)
Post translational modification of serum TTR (1996) (5)
C-reactive protein. A review of its structure and function. (1982) (5)
Beta-edge interactions in a pentadecameric human antibody V kappa domain. (2007) (5)
STUDIES ON THE PRIMARY STRUCTURE OF MOUSE SERUM AMYLOID P COMPONENT (SAP) (1982) (4)
C-Reactive Protein in Myocardial Infarction and Ischaemia (1982) (4)
Role of heart transplantation in systemic amyloidosis. (1996) (4)
Binding of factor H to C-reactive protein occurs only when the latter has undergone non-physiologic denaturation (2007) (4)
NON-INVASIVE DEMONSTRATION OF CARDIAC INVOLVEMENT IN ACQUIRED FORMS OF SYSTEMIC AMYLOIDOSIS (1984) (4)
Role of the acute phase response in the Shwartzman phenomenon. (1982) (4)
Circulating immunoglobulins and complement in mice with Hymenolepis nana infection. (1984) (4)
Amyloid damage to islet β-cells in type 2 diabetes: hypoxia or pseudo-hypoxia? (2019) (4)
Complement in the Induction of IgA and IgE Antibody Production (1976) (4)
Dose-Dependent Progressive Immunotherapeutic Clearance of Systemic Amyloid Deposits By Repeated Doses of Antibody to Serum Amyloid P Component (SAP) (2015) (4)
Binding of C4-binding protein by aggregated serum amyloid P component (1982) (4)
Crystallizations of human serum amyloid P component (SAP) (1988) (4)
Isolation and characterisation of goat C-reactive protein. (1987) (4)
A New Deletion Mutation of the Apolipoprotein Ai Gene Causing Hereditary Amyloidosis (1996) (4)
Continuous Subcutaneous Insulin Infusion Does Not Provoke Significant Acute-Phase Response (1986) (4)
Epileptic discharges produced in monkeys by injection of spleen cells from rabbits immunised with monkey brain (1981) (4)
SAP Scintigraphy in 43 patients with TTR-associated FAP (1996) (4)
Preparative isolation of human β2-microglobulin from urine (1990) (3)
Demonstration of lymphocyte surface markers using alkaline phosphatase-labeled reagents. Application to the enumeration of lymphocyte populations in whole peripheral blood. (1983) (3)
DIAGNOSIS OF CHEST PAIN IN MARATHON RUNNERS (1984) (3)
Analysis of X-Ray Scattering by Human AA Fibrils Using Secondary Structure Predictions of Human SAA1 (1986) (3)
Liver Transplantation in ATTR Met30 and Other Variants: Time to Shift the Paradigm? (2004) (3)
Therapeutic Inhibition of C-Reactive Protein-Novel Drugs, Novel Mechanisms (2003) (3)
Immuno histochemical studies of amyloid p component in normal and diseased skin (1981) (3)
Phenotype, Genotype and Outcome in Hereditary ApoAI Amyloidosis (2004) (3)
Effect of vitamin C dietary supplementation on survival in amyloidosis. (1987) (3)
Acute Phase Proteins (1998) (3)
A novel complex indel mutation in the fibrinogen aβ chain gene in an asian child with systemic amyloidosis (2004) (3)
Immunotherapeutic clearance of systemic amyloid deposits by antibodies to serum amyloid P component (2017) (3)
High dose chemotherapy for systemic AL amyloidosis. (1999) (3)
Classical and alternative pathway complement activation are not required for reactive systemic AA amyloid deposition in mice (2004) (2)
SerumC-reactive protein measurement inthe detection ofintercurrent infection inOriental patients withsystemic lupus erythematosus (1985) (2)
Combination chemotherapy for systemic AL amyloidosis (2001) (2)
Bifunctional crosslinking ligands for transthyretin (2015) (2)
Dementia in the older population is associated with neocortex content of serum amyloid P component (2021) (2)
A new immunoassay for C3. Application of the cell-linked antigen radioactive antibody (CLARA) technique. (1975) (2)
From genetics to pathology: tau and α-synuclein assemblies in neurodegenerative diseases - Discussion (2001) (2)
Dame Sheila Patricia Violet Sherlock. 31 March 1918 – 30 December 2001 Elected FRS 2001 (2003) (2)
COMPONENT FOR THE PYRUVATE ACETAL OF GALACTOSE (1984) (2)
ALK amyloid in a solitary extradural lymphoma (2)
Continuous subcutaneous insulin infusion does not induce a significant acute phase response of serum amyloid A protein (1985) (2)
Attention to detail in the selection of words in epidemiologic research reports. (2014) (2)
Scintigraphic Imaging of Amyloidosis with 123Iodine Serum Amyloid P Component (1991) (2)
Does Serum Degrade Amyloid Fibrils? Failure to Confirm Enzymatic Degradation of Amyloid A Fibrils as the Basis of the so-called “Amyloid Degrading Activity” of Serum (1986) (2)
Serum C-reactive protein response to therapeutic embolisation: possible role in management. (1985) (2)
INVIVO TURNOVER STUDIES OF RADIOIODINATED C-REACTIVE PROTEIN IN MAN (1992) (2)
Role of complement in infectious disease (1978) (2)
Report of Special Session on Bioassays and Standardization of Amyloid Proteins and Precursors (1991) (2)
Significance of CRP elevation in SLE. (1983) (2)
Serum Amyloid P-Component: Binding to Amyloid Fibrils and Immunohistochemical Staining in Normal Human Tissues (1980) (1)
Imaging of Amyloid Deposits in vivo (1988) (1)
Scintigraphic imaging and turnover studies with (131) I-serum amyloid P component (SAP) in systemic amyloidosis (1999) (1)
Academia Big Pharma collaboration in drug development (2014) (1)
SAA(1) alleles as risk factors in AA amyloidosis (1999) (1)
Natural history of hereditary lysozyme amyloidosis (2010) (1)
Proceedings: Antigen binding cells in rabbit Peyer's patches after intestinal immunisation. (1976) (1)
Isolation and Characterisation of the Integral Glycosaminoglycan Constituents of Human AA and AL Amyloid Fibrils (1991) (1)
Imaging amyloidosis in Still's disease. (1989) (1)
Stable Evolutionary Conservation of Complement-Activating and Related Pentagonal Serum Proteins: C-reactive Protein and Protein SAP (1978) (1)
Reply to: Avoiding the effect of linked genes is crucial to elucidate the role of Apcs in autoimmunity (2005) (1)
Macrophage dependent elimination of amyloid following treatment with anti-SAP antibody (2010) (1)
Controllable expression of SAA in transgenic mice: a refined model of systemic amyloidosis (2010) (1)
Serum Amyloid P Component: A Specific Molecular Targeting Vehicle in Amyloidosis (1989) (1)
C-reactive protein and coronary heart disease - Reply (2004) (1)
C-reactive protein and social status (2001) (1)
C-reactive protein and cardiovascular disease: Weighing the evidence (2007) (1)
Molecular Mechanisms of Amyloid Fibril Formation: The Lysozyme Model (1996) (1)
Sepharose‐C3 (1976) (1)
Proceedings: Complement dependence of IgA antibody production. (1975) (1)
Jack Pepys (May 15, 1914-September 9, 1996): a personal recollection. (2009) (1)
484 patients serum amyloid P component scintigraphy in I 123 The liver in systemic amyloidosis : insights from (1998) (1)
ANTICYTOPLASMIC ANTIBODIES IN WEGENER'S GRANULOMATOSIS (1985) (1)
Fibrinogen a α-chain amyloidosis: Clinical features and outcome after hepatorenal or solitary kindey transplantation (2004) (1)
Progressive restrictive cardiomyopathy following orthotopic liver transplantation for familial amyloid polyneuropathy. (1997) (1)
A prospective study of sICAM-1, low level CRP and SAA in neonatal infection (1998) (1)
Imaging Hereditary Amyloidosis of Ostertag (1991) (1)
Infection With Helicobacter pyloriIs Not a Major Independent Risk Factor for Stable Coronary Heart Disease Lack of a Role of Cytotoxin-Associated Protein A–Positive Strains and Absence of a Systemic Inflammatory Response (1999) (1)
Fibrinogen A alpha-chain amyloidosis: Clinical features and the role of combined liver and kidney transplantation (2005) (0)
Human Serum Amyloid P Decreases Shigatoxin 2 Induced Activation of Mitogen Activated Protein Kinases and Apoptosis in Human Podocytes (2013) (0)
The structure of serum amyloid p component bound to phosphoethanolamine (2010) (0)
Association of smoking with markers of systemic inflammation: results of a population-based study (2002) (0)
Circulating humanleucocyte elastase inpatients with inflammatory bowel disease (1985) (0)
Avoiding the effect of linked genes is crucial to elucidate the role of Apcs in autoimmunity - Reply (2005) (0)
Natural History and Regression of Amyloidosis Demonstrated by Serum Amyloid P Component Scintigraphy (1993) (0)
Anti-sap antibodies and sap depleting compounds for the treatment of amyloidosis (2008) (0)
Three-dimensional structure of human C-reactive protein (1996) (0)
The Acute Phase Response Enhances Resistance to Bacterial Infections (2000) (0)
The Three Dimensional Structure of SAP (1989) (0)
LIVER TRANSPLANTATION FOR END STAGE HEPATIC AMYLOIDOSIS. (2000) (0)
Structural and Functional Studies of Serum Amyloid P Component (1991) (0)
Today February 1982 C-reactive protein and the acute phase response from (2004) (0)
Research Highlights (2006) (0)
Amyloid and immunotactoid glomerulopathy (2008) (0)
Is Serum Amyloid P Component Required for in Vivo Amyloid Deposition (1996) (0)
Secondary Structure Prediction of Human AA Protein (1987) (0)
t argeted t reatment for amyloidosis (2014) (0)
Hereditary amyloidosis - Reply (2002) (0)
LIVER TRANSPLANTATION FOR END STAGE HEPATIC AMYLOIDOSIS.: Abstract# 105 (2000) (0)
Prions and the lymphoreticular system - Discussion (2001) (0)
New variants of apoAI. The first deletion mutations causing hereditary amyloidosis. (1996) (0)
Serum Amyloid Degrading Activity (1983) (0)
The structure of C-reactive protein bound to phosphoethanolamine (2010) (0)
The structure of serum amyloid P component bound to 0-phospho- threonine (2009) (0)
Calcium dependent by pentraxins to ligands immobilized on agarose, and effect of C-reactive protein on leptin action in mice in vivo (2007) (0)
Preparative isolation of human beta 2-microglobulin from urine. (1990) (0)
Sensitive MRI markers for systemic amyloidosis : amide proton transfer and equilibrium contrast (2010) (0)
Inhibition of the mechano-enzymatic amyloidogenesis of transthyretin: role of ligand affinity, binding cooperativity and occupancy of the inner channel (2017) (0)
Serum Amyloid P Component Scintigraphy in Alzheimer's Disease (1996) (0)
Amyloidosis, protein folding and SAP (2000) (0)
TTR mutations in 2 patients wtph a clinical diagnosis of senile cardiac amyloidosis (1996) (0)
Serum C-Reactive Protein in the Rapid Diagnosis of Bacterial Infection during Sickle Cell Crisis: A Preliminary Report (1984) (0)
Ligand Specificity of Serum Amyloid P Component (1983) (0)
THU0379 A 20 year single centre experience of aa amyloidosis demonstrating changes in its epidemiology (2013) (0)
The three-dimensional structure of human serum amyloid P-component defined at 2.0 Å reveals a lectin like fold and calcium mediated ligand binding (1993) (0)
C-reactive Protein and other Acute Phase Reactants (1983) (0)
Transthyretin amyloidosis: new answers but many questions (2021) (0)
Normal Human Serum Transthyretin Displays Post-Translational Modifications (1996) (0)
The natural history of hepatic amyloidosis: insights from 123I-SAP scintigraphy in 484 patients (1998) (0)
Lipoprotein Binding by Aggregated C-Reactive Protein (1982) (0)
Dementia and neurodegeneration : Challenges and opportunities Fundamental research : From molecules to neural circuitry (2013) (0)
Sepharose‐C3 (1976) (0)
Recurrent polyserositis (familial mediterranean fever, periodic disease) by M. Eliakim, M. Levy and M. Ehrenfeld, Elsevier/North-Holland (1981) Dfl 140.00 (x + 227 pages) ISBN 0-444-80331-9. (1982) (0)
Serum Amyloid P Component co-crystallised with MOBDG at neutral pH (2003) (0)
Fibrinogen Aα-chain Amyloidosis: Clinical features and the role of combined liver and kidney transplantation. (2005) (0)
therapeutic agent for the elimination of a population of proteins unwanted plasma. (2002) (0)
Anti-nuclear autoimmunity in mice with targeted deletion of serum amyloid P component. (1998) (0)
RapidAutomatedEnzymeImmunoassay of SerumAmyloidA (1994) (0)
Alpha-1 antiprotease alleles as risk factors in AA amyloidosis (1999) (0)
Monitoring amyloid deposition and therapeutic clearance using equilibrium contrast MRI (2011) (0)
DECAMERIC DAMP COMPLEX OF HUMAN SERUM AMYLOID P COMPONENT (1997) (0)
Resistance to Bacterial Infection Acute Phase Response Enhances Host Colony-Stimulating Factor in the Nonspecific Production of Granulocyte (2002) (0)
Novel palindromic ligands cementing the native quaternary structure of transthyretin (2010) (0)
II.4 AMYLOID P-COMPONENT: STRUCTURE AND PROPERTIES (1986) (0)
lymphoma . AL kappa amyloid in a solitary extradural (0)
Ligand binding to pentraxins (2008) (0)
C-reactive protein alters vascular reactivity by increasing nitric oxide production (2003) (0)
Treating amyloid in the periphery and the brain (2002) (0)
REGRESSION OF AMYLOIDOSIS DEMONSTRATED BY SAP SCINTIGRAPHY (1993) (0)
Pathogenetic mechanisms of AA amyloidosis Short title : Pathogenesis of AA amyloidosis (2013) (0)
in Mice against Acute Lipopolysaccharide Challenge Human C-Reactive Protein Does Not Protect (2003) (0)
Temperature dependence of antigen-specific rosette formation by lymphocytes from immunised mice. (1977) (0)
A pilot study of the tolerability, safety and efficacy of CPHPC in patients with systemic amyloidosis (2006) (0)
Transthyretin amyloidosis – insights from neutron crystallography (2011) (0)
P2-307: CPHPC depletes serum amyloid P component from the cerebrospinal fluid in Alzheimer's disease (2008) (0)
Combinaisons d'agents d'appauvrissement et d'anticorps anti-sap (2008) (0)
Human Transthyretin (TTR) complexed with a palindromic bivalent amyloid inhibitor (11 carbon linker). (2010) (0)
Mechano-enzymatic cleavage and TTR amyloidogenesis (2017) (0)
New Images of Clinical Amyloidosis (1991) (0)
Circadian Rhythm of Salivary Cortisol, 17 (cid:2) -Hydroxy-progesterone, and Progesterone in Healthy Children, (2003) (0)
Serum amyloid P component in autoimmune mice (1982) (0)
Ten-Year Clinical and Angiographic Follow-Up of Coronary Wallstent (2000) (0)
New therapeutic perspectives – amyloid removal (2015) (0)
Crystallographic Analysis of Human Serum Amyloid P Component (1988) (0)
Transthyretin mutations in amyloidosis (1999) (0)
A Primed State Exists in vivo Following Regression of Murine AA Amyloidosis (1991) (0)
Crystallographic studies of the human pentraxins, serum amyloid P component and C-reactive protein (1996) (0)
13th Meeting of the Clinical Autonomic Research Society: Abstracts (2005) (0)
Clinical Features, Diagnosis and Treatment of Familial Amyloid Polyneuropathy (1996) (0)
Left Atrial Myxoma Associated With (2017) (0)
Scintigraphic Imaging of Amyloid Deposits Using Technetium-Labelled Serum Amyloid P Component (1996) (0)
Compounds that inhibit binding of SAP to treat osteoarthritis. (2004) (0)
Title Structure , Folding Dynamics , and Amyloidogenesis of D 76 N β 2-Microglobulin : ROLES OF SHEAR FLOW , HYDROPHOBIC SURFACES (0)
Transthyretin Glu18, A New Variant Associated With Familial Amyloid Polyneuropathy (1998) (0)
Human C-Reactive Protein Binds Circulating Very Low Density Lipoproteins (1984) (0)
Amyloidosis: disease caused by amyloid (2007) (0)
X-ray crystallographic studies of human serum amyloid P-component (SAP) (1987) (0)
Interaction Between Lymphocytes and Fluid Phase Murine and Human C3b (1978) (0)
Systemic markers of inflammation do not predict coronary in-stent restenosis in stable angina patients treated with HMG CoA reductase inhibitors (2003) (0)
Nature and specificity of binding of serum amyloid P component to amyloid fibrils (1999) (0)
Dame Sheila Patricia Violet Sherlock. (2003) (0)
Stabilization and inhibition of amyloidogenesis by a new palindromic ligand of transthyretin (2011) (0)
Nature and specificity of amyloid fibril binding by serum amyloid P component (1999) (0)
133. Targeted deletion of the serum amyloid P component gene does not affect scrapic pathogenesis in mice (2002) (0)
Inhibition of Binding of Serum Amyloid P Component to Amyloid Fibrils, Fibronectin and C4-Binding Protein (1984) (0)
Serum amyloid P component is a constituent of normal adult mammalian glomeruli (2010) (0)
Erratum: Intensive chemotherapy for al amyloidosis (Clinical Science (1996) 90) (1996) (0)
Serum amyloid P and fibrosis in systemic sclerosis: comment on the article by Terment et al - Reply (2007) (0)
Serum C-Reactive Protein in Polymyalgia Rheumatica: A Prospective Serial Study (1984) (0)
Serum Amyloid P Component as a Therapeutic Target in Amyloidosis (2004) (0)
In-Vivo Turnover Studies of Rabbit C-Reactive Protein and Lipoproteins (1984) (0)
The Interaction of Very Low Density Lipoprotein and Low Density Lipoprotein with Rabbit and Rat C-Reactive Protein (1983) (0)

This paper list is powered by the following services:

Other Resources About Mark Pepys

What Schools Are Affiliated With Mark Pepys?

Mark Pepys is affiliated with the following schools: